Trials / Recruiting
RecruitingNCT06292286
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
Detailed description
Our study aims to evaluate the complete resection rate at interval cytoreductive surgery for recurrent ovarian cancer patients, and to determine the safety and survival outcomes of this approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Carboplatin or cisplatin | Carboplatin of cisplatin for 3-6 cycles |
| DRUG | Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar | Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles |
| DRUG | Bevacizumab or biosimilar | Optional |
| PROCEDURE | Cytoreductive surgery | Cytoreductive surgery after chemotherapy |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-03-05
- Last updated
- 2025-06-11
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06292286. Inclusion in this directory is not an endorsement.